Repligen Announces Identification Of Drug Target For Friedreich's Ataxia

Repligen Corporation (Nasdaq: RGEN) reported publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia.